1 / 7

P1060 commentary

P1060 commentary. Philippa Musoke MBChB Makerere University –Johns Hopkins University Research Collaboration, Kampala Uganda. Cohort 1. NVP exposed infants with higher treatment failure rates on a NVP based regimen Emergence of NVP resistance after sd NVP

astin
Download Presentation

P1060 commentary

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. P1060 commentary Philippa Musoke MBChB Makerere University –Johns Hopkins University Research Collaboration, Kampala Uganda

  2. Cohort 1 • NVP exposed infants with higher treatment failure rates on a NVP based regimen • Emergence of NVP resistance after sd NVP • There are higher rates of NNRTI resistance after prolonged NVP prophylaxis • Recommendation • Children below 2 years of age • PI as 1st line therapy should be the standard of care BUT • Option for use of NVP where PIs unavailable • Children > 2 years • NVP based regimen as 1st line regimen

  3. Challenge of 1st line PI regimenin NVP exposed children • Large numbers of NVP exposed children expected • Can all countries afford scale up of PI based 1st line ART ? • If PMTCT coverage is high then • Fewer HIV infected children but .. • Implementation of PI based regimens – more complex • Syrup requires refrigeration • Tablet 100mg ( Alluvia) can not be cut in half • Lack of a fixed dose combination • More expensive than NNRTIs • Not widely available in many resource limited settings Protease Inhibitors need to be made available for these children

  4. Cohort II • NVP unexposed - baseline NNRTI resistance should not be an issue • Previous studies have shown treatment success with NVP > 70 % virological success at 24 – 48 wks • P1060 NVP arm, had higher treatment failure • Adherence to syrups vs FDC ? • Lead in phase of NVP - emergence of resist. ? • Subtype C – higher rates of NNRTI resistance ?

  5. Challenge of implementation of PI in non exposed children • Implementation of PI based regimen for all HIV infected children under 2 years • This may be feasible for some RLS – S Africa • May not as feasible other countries • Zimbabwe ?, Malawi ?, Tanzania ? , Uganda ? • There should be an option for children NOT exposed to NVP to initiate a NVP based regimen • Need to ensure good adherence and close monitoring • Not easy to detect early treatment failure without access to viral loads

  6. Immune response and Growth • Wide scale implementation of PI in infants may affect future growth of these infected children • Critical issue in view of the high rates of malnutrition and food insecurity • Do the children gain weight more slowly but catch up over time ? • Needs further follow up ( Version 5.0)

  7. Summary • NVP exposed HIV infected children • Every effort should be made to make PIs available for these children • Development of FDC of AZT/3TC/LPV/r a priority, if we are to scale up early initiation of ART • Where there are no PIs children should not be denied ART • Non-exposed HIV infected children • Where PIs are available they may be used BUT • NVP based 1st line regimen should still remain an option for this group of children ( 60% had treatment success) • However, some may feel it is easier to have one 1st line regimen for all infants BUT $$$$$$

More Related